Factors Affecting Long-Term Expression of a Secreted Transgene Product after Intravenous Administration of a Retroviral Vector
Open Access
- 30 April 2001
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 3 (4) , 516-525
- https://doi.org/10.1006/mthe.2000.0259
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Tri-iodothyronine and a deleted form of hepatocyte growth factor act synergistically to enhance liver proliferation and enable in vivo retroviral gene transfer via the peripheral venous systemGene Therapy, 2000
- Effective repeat administration with adenovirus vectors to the muscleGene Therapy, 2000
- Human Gene Marker/Therapy Clinical Protocols (Complete Updated Listings)Human Gene Therapy, 1999
- Generation of a Systemic Antitumor Response with Regional Intratumoral Injections of InterferonγRetroviral VectorHuman Gene Therapy, 1998
- Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy.Journal of Clinical Investigation, 1998
- Anti-Vector Immunoglobulin Induced by Retroviral VectorsHuman Gene Therapy, 1997
- Establishment of Parameters for Optimal Transduction Efficiency and Antitumor Effects with Purified High-Titer HSV-TK Retroviral Vector in Established Solid TumorsHuman Gene Therapy, 1997
- Delayed-Type Hypersensitivity Response to High Doses of Adenoviral VectorsHuman Gene Therapy, 1997
- Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes.Journal of Clinical Investigation, 1996
- Long-Term Improvement of Hypercholesterolemia After Ex Vivo Gene Therapy in LDLR-Deficient RabbitsScience, 1991